{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-23-000026","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.852207+00:00","generated_at":"2026-06-16T08:02:45.159871+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PTC Therapeutics Q1 rev $220M (+48% YoY), DMD $170M; FY23 guidance reaffirmed","bullets":["Total revenue $220.4M vs $148.7M YoY (+48%); net product revenue $187.6M vs $129.8M.","Translarna net revenue $115.1M (+45% YoY); Emflaza $54.6M (+12% YoY); Evrysdi royalty $30.8M (+63%).","GAAP net loss $139.0M vs $126.7M; cash $286.3M at quarter-end vs $410.7M at Dec 31.","Reaffirmed FY2023 total revenue guidance $940M-$1.0B; DMD franchise $545-565M.","Four clinical readouts expected in Q2 2023, incl. registration trials for sepiapterin (PKU), vatiquinone (FA & mito disease), and PTC518 (HD) interim data."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-23-000026","json":"https://secwatch.observer/filing/0001070081-23-000026.json","markdown":"https://secwatch.observer/filing/0001070081-23-000026.md","text":"https://secwatch.observer/filing/0001070081-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/0001070081-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/tmb-20230427x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:02:45.159871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"394d11994a4eb3e3ed0b5704b23753d2fe0d527e","claim":"PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2023 results: revenue $220.4 million. Guidance reaffirmed.","evidence_excerpt":"this Item 2.02. ​ --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results – First-quarter 2023 total revenue of $220 million, representing 48% year-over-year growth - ​ – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed – ​ SOUTH","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/0001070081-23-000026-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2023"},{"label":"Revenue","value":"$220.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}